Search Results - multivalent

4 Results

Sort By:

Dengue Vaccines: Tools for Redirecting the Immune Response for Safe, Efficacious Dengue Vaccination

This CDC-developed invention relates to dengue vaccines that have been specifically developed for improved efficacy and directed immune response to avoid antibody-dependent enhancement (ADE) safety issues that, theoretically, may be associated with dengue vaccines and vaccinations. Dengue viral infection typically causes a debilitating but non-lethal...

Published: 7/25/2024 | Inventor(s): Wayne Crill, Holly Hughes, Brent Davis, Gwong-Jen Chang

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Containing, Cross-Reactive, DB4BXX, DB4XXX, DC5BXX, DC5XXX, DCXXXX, DDXXXX, DENGUE, DNA vaccine, DXXXXX, E-GLYCOPROTEIN, Eliminate, Epitopes, Immunodominant, insect, Insects, Mosquito, Mosquitoes, MULTIVALENT, Mutations, OID-NCEZID-DVBD, POLYPEPTIDES, Serotype, Serotypes, That, Vacccination, Vaccine, Vector-borne, Vector-borne diseases, virus, VLXXXX, WJXXXX, WMXXXX, XCXXXX, XEXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Consumer Products, Application > Research Materials, Application > Diagnostics

Multivalent, Multiple-Antigenic-Peptides for Serological Detection of HIV-1 Groups -M, -N, -O, and HIV-2

This CDC-developed invention pertains to multivalent antigenic peptides (MAPs) that can be used in a variety of HIV/AIDS diagnostics. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is subdivided into groups M, N, and O, while HIV-2 is subdivided into subtypes A and B. Within HIV -1 group M, several different subtypes and numerous forms of recombinant...

Published: 7/25/2024 | Inventor(s): Chou-Pong Pau

Keywords(s): 0, AAXXXX, AIDS, antibodies, ANTIGEN, AXXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA4AXX, DA4XXX, DAXXXX, Detection, DEVELOPING, DXXXXX, GROUP, HIV-1, HIV-2., LATERAL, M, MAPS, Multiple-antigenic-peptides, MULTIVALENT, N, RESEARCH MATERIAL, virus, VLXXXX, WBXXXX, WFXXXX, WIXXXX, XAXXXX, XCXXXX, XEXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Infectious Disease, Application > Occupational Safety and Health, Application > Therapeutics, Application > Consumer Products

HIV-1 Multi-Clade, Multivalent Recombinant Vaccine Construct

CDC scientists developed immunogenic multi-clade, multivalent (HIV1MCMV) recombinant constructs for use as HIV-1 vaccines. These polypeptides include immunogenic CTL, T- and/or B-cell determinants that are capable of eliciting broad and effective immune responses against diverse subtypes of HIV-1. It is believed that these HIV-1 constructs provide universal...

Published: 7/25/2024 | Inventor(s): Sherry Owen, Renu Lal

Keywords(s): CDC Docket Import, CDC Docket Import CDC Prosecuting, Constructs, DB4AXX, DB4XXX, DBXXXX, DC1XXX, DC5AXX, DC5XXX, DCXXXX, HIV-1, Immunogenic, Methods, Multi-clade, MULTIVALENT, OID-NCHHSTP-DHPSE, Their

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Therapeutics

A Novel Scaffold for Multivalent Display of Ligands

Multivalent interactions are important in cell attachment, wound healing and immune responses. Such interactions are associated with cancer metastasis, blood clotting and the generation of antibodies from a vaccination. Mimicking multivalent interactions on a synthetic scaffold is challenging especially when large numbers of ligands (such as 5 or more)...

Published: 7/25/2024 | Inventor(s): Daniel Appella

Keywords(s): AAXXXX, AXXXXX, Based, Chain-Modified, DISPLAY, LIGANDS, MULTIVALENT, Nanostructures, PNA, PNAfor, PROGRAMMABLE, Self-assembled, SIDE, Sidechain-Modified, YXXXXX

Category(s): Collaboration Sought > Collaboration